Assignee
JIANGSU KANION PHARMACEUTICAL CO LTD
CN·12 granted patents·9 pending applications·2 citations·filing 2015–2023
Top patents by PatentIndex Score
21 records- 0175US9988361B2Anti-enterovirus 71 thiadiazolidine derivativeJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2015·Granted Jun 5, 2018·2 cites·7 claims
- 0260US11814352B2Salts formed by 2-(1-acyloxy-n-pentyl) benzoic acid and basic amino acid or aminoguanidine, and preparation method and application thereofJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 14, 2023·0 cites·10 claims
- 0359US2026077041A1BISPECIFIC FUSION PROTEIN TARGETING TNF-a AND IL-17A, AND USE THEREOFJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0458US11958860B2Crystal form of compound, and preparation method therefor and use thereofJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2021·Granted Apr 16, 2024·0 cites·9 claims
- 0557US12565477B2Preparation method for chlorinated compoundJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2021·Granted Mar 3, 2026·0 cites·13 claims
- 0657US2024383906A15-substituted pyridine-2(1h)-ketone compound and use thereofJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0757US2025241975A1A traditional chinese medicine composition, and preparation method therefor and use thereofJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0856US12409192B2Traditional Chinese medicine composition and use thereofJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2022·Granted Sep 9, 2025·0 cites·9 claims
- 0955US11564904B2Gingko diterpene lactone compositionJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2018·Granted Jan 31, 2023·0 cites·7 claims
- 1055US11524041B2Ginkgo diterpene lactone compositionJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2018·Granted Dec 13, 2022·0 cites·10 claims
- 1154US12497463B2Anti-CD38 antibody and use thereofJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2021·Granted Dec 16, 2025·0 cites·26 claims
- 1251US12558394B2Application of traditional Chinese medicine composition to preparation of medicine for treating or preventing coronavirus infectionJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2021·Granted Feb 24, 2026·0 cites·7 claims
- 1346US12365686B2Compound as porcupine inhibitor and use thereofJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2020·Granted Jul 22, 2025·0 cites·16 claims
- 1446US2023263789A1Pharmaceutical composition and preparation methodJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1546US2023135963A1Anti-arrhythmic pharmaceutical composition and preparation method thereforJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1646US2023080878A1Application of traditional chinese medicine composition in preparation of drugs for treating or preventing coronavirus infectionJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 1745US2020350058A1Chinese medicine production process knowledge systemJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2018·Application pending·0 cites
- 1844US11254635B2Emodin succinyl ester compound, preparation method therefor and application thereofJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2018·Granted Feb 22, 2022·0 cites·15 claims
- 1944US2023173006A1Application of traditional chinese medicine composition to preparation of medicine for treating or preventing coronavirus infectionJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2044US2023173011A1Application of traditional chinese medicine composition to preparation of medicine for treating or preventing coronavirus infectionJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2134US11576942B2Traditional Chinese medicine composition and preparation method and application thereofJIANGSU KANION PHARMACEUTICAL CO LTD·Filed 2019·Granted Feb 14, 2023·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when JIANGSU KANION PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →